Chris LearnVice President, Cell and Gene Therapy at Parexel
20+ years of trial execution and team management experience. Team leader in the registrational development, agency submission and regulatory approval of Imbruvica®, Yondelis® and Keytruda®, as well as Yescarta® clinical development, following initial market authorization. Also oversaw the outsourced global trialing operations for the clinical development of CAR-T assets Lisocabtagene Maraleucel (liso-cel) and Idecabtagene Vicleucel (ide-cel) currently under BLA review at FDA.
Previously Senior Director, Clinical Development at Istari Oncology, Senior Director Cell & Gene Therapy Center of Excellence at IQVIA, and Program Manager Oncology/Hematology at ICON
Wake Forest University, Doctor of Philosophy, Microbiology and Immunology; Virginia Tech, Biology, Chemistry